Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease

Seon Ha Baek, Ran Hui Cha, Shin Wook Kang, Cheol Whee Park, Dae-Ryong Cha, Sung Gyun Kim, Sun Ae Yoon, Sejoong Kim, Sang Youb Han, Jung Hwan Park, Jae Hyun Chang, Chun Soo Lim, Yon Su Kim, Ki Young Na

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Patients with chronic kidney disease (CKD) have been found to show markedly increased rates of end-stage renal disease, major adverse cardiovascular and cerebrovascular events (MACCEs), and mortality. Therefore, new biomarkers are required for the early detection of such clinical outcomes in patients with CKD. We aimed to determine whether the level of circulating renalase was associated with CKD progression, MACCEs, and all-cause mortality, using data from a prospective randomized controlled study, Kremezin STudy Against Renal disease progression in Korea (K-STAR; NCT00860431). METHODS: A retrospective analysis of the K-STAR data was performed including 383 patients with CKD (mean age, 56.4 years; male/female, 252/131). We measured circulating renalase levels and examined the effects of these levels on clinical outcomes. RESULTS: The mean level of serum renalase was 75.8 ± 34.8 μg/mL. In the multivariable analysis, lower hemoglobin levels, higher serum creatinine levels, and diabetes mellitus were significantly associated with a higher renalase levels. Over the course of a mean follow-up period of 56 months, 25 deaths and 61 MACCEs occurred. Among 322 patients in whom these outcomes were assessed, 137 adverse renal outcomes occurred after a mean follow-up period of 27.8 months. Each 10- μg/mL increase in serum renalase was associated with significantly greater hazards of all-cause mortality and adverse renal outcomes (hazard ratio [HR] = 1.112, p = 0.049; HR = 1.052, p = 0.045). However, serum renalase level was not associated with the rate of MACCEs in patients with CKD. CONCLUSION: Our results indicated that circulating renalase might be a predictor of mortality and adverse renal outcomes in patients with CKD.

Original languageEnglish
Pages (from-to)858-866
Number of pages9
JournalThe Korean journal of internal medicine
Volume34
Issue number4
DOIs
Publication statusPublished - 2019 Jul 1

Fingerprint

Chronic Renal Insufficiency
Kidney
Mortality
Serum
Disease Progression
Korea
renalase
Chronic Kidney Failure
Creatinine
Diabetes Mellitus
Hemoglobins
Biomarkers

Keywords

  • Chronic kidney disease
  • End-stage renal disease
  • Mortality
  • Renalase

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease. / Baek, Seon Ha; Cha, Ran Hui; Kang, Shin Wook; Park, Cheol Whee; Cha, Dae-Ryong; Kim, Sung Gyun; Yoon, Sun Ae; Kim, Sejoong; Han, Sang Youb; Park, Jung Hwan; Chang, Jae Hyun; Lim, Chun Soo; Kim, Yon Su; Na, Ki Young.

In: The Korean journal of internal medicine, Vol. 34, No. 4, 01.07.2019, p. 858-866.

Research output: Contribution to journalArticle

Baek, SH, Cha, RH, Kang, SW, Park, CW, Cha, D-R, Kim, SG, Yoon, SA, Kim, S, Han, SY, Park, JH, Chang, JH, Lim, CS, Kim, YS & Na, KY 2019, 'Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease', The Korean journal of internal medicine, vol. 34, no. 4, pp. 858-866. https://doi.org/10.3904/kjim.2017.058
Baek, Seon Ha ; Cha, Ran Hui ; Kang, Shin Wook ; Park, Cheol Whee ; Cha, Dae-Ryong ; Kim, Sung Gyun ; Yoon, Sun Ae ; Kim, Sejoong ; Han, Sang Youb ; Park, Jung Hwan ; Chang, Jae Hyun ; Lim, Chun Soo ; Kim, Yon Su ; Na, Ki Young. / Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease. In: The Korean journal of internal medicine. 2019 ; Vol. 34, No. 4. pp. 858-866.
@article{27ed69d63216415887abae22cdb314be,
title = "Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease",
abstract = "BACKGROUND/AIMS: Patients with chronic kidney disease (CKD) have been found to show markedly increased rates of end-stage renal disease, major adverse cardiovascular and cerebrovascular events (MACCEs), and mortality. Therefore, new biomarkers are required for the early detection of such clinical outcomes in patients with CKD. We aimed to determine whether the level of circulating renalase was associated with CKD progression, MACCEs, and all-cause mortality, using data from a prospective randomized controlled study, Kremezin STudy Against Renal disease progression in Korea (K-STAR; NCT00860431). METHODS: A retrospective analysis of the K-STAR data was performed including 383 patients with CKD (mean age, 56.4 years; male/female, 252/131). We measured circulating renalase levels and examined the effects of these levels on clinical outcomes. RESULTS: The mean level of serum renalase was 75.8 ± 34.8 μg/mL. In the multivariable analysis, lower hemoglobin levels, higher serum creatinine levels, and diabetes mellitus were significantly associated with a higher renalase levels. Over the course of a mean follow-up period of 56 months, 25 deaths and 61 MACCEs occurred. Among 322 patients in whom these outcomes were assessed, 137 adverse renal outcomes occurred after a mean follow-up period of 27.8 months. Each 10- μg/mL increase in serum renalase was associated with significantly greater hazards of all-cause mortality and adverse renal outcomes (hazard ratio [HR] = 1.112, p = 0.049; HR = 1.052, p = 0.045). However, serum renalase level was not associated with the rate of MACCEs in patients with CKD. CONCLUSION: Our results indicated that circulating renalase might be a predictor of mortality and adverse renal outcomes in patients with CKD.",
keywords = "Chronic kidney disease, End-stage renal disease, Mortality, Renalase",
author = "Baek, {Seon Ha} and Cha, {Ran Hui} and Kang, {Shin Wook} and Park, {Cheol Whee} and Dae-Ryong Cha and Kim, {Sung Gyun} and Yoon, {Sun Ae} and Sejoong Kim and Han, {Sang Youb} and Park, {Jung Hwan} and Chang, {Jae Hyun} and Lim, {Chun Soo} and Kim, {Yon Su} and Na, {Ki Young}",
year = "2019",
month = "7",
day = "1",
doi = "10.3904/kjim.2017.058",
language = "English",
volume = "34",
pages = "858--866",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "4",

}

TY - JOUR

T1 - Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease

AU - Baek, Seon Ha

AU - Cha, Ran Hui

AU - Kang, Shin Wook

AU - Park, Cheol Whee

AU - Cha, Dae-Ryong

AU - Kim, Sung Gyun

AU - Yoon, Sun Ae

AU - Kim, Sejoong

AU - Han, Sang Youb

AU - Park, Jung Hwan

AU - Chang, Jae Hyun

AU - Lim, Chun Soo

AU - Kim, Yon Su

AU - Na, Ki Young

PY - 2019/7/1

Y1 - 2019/7/1

N2 - BACKGROUND/AIMS: Patients with chronic kidney disease (CKD) have been found to show markedly increased rates of end-stage renal disease, major adverse cardiovascular and cerebrovascular events (MACCEs), and mortality. Therefore, new biomarkers are required for the early detection of such clinical outcomes in patients with CKD. We aimed to determine whether the level of circulating renalase was associated with CKD progression, MACCEs, and all-cause mortality, using data from a prospective randomized controlled study, Kremezin STudy Against Renal disease progression in Korea (K-STAR; NCT00860431). METHODS: A retrospective analysis of the K-STAR data was performed including 383 patients with CKD (mean age, 56.4 years; male/female, 252/131). We measured circulating renalase levels and examined the effects of these levels on clinical outcomes. RESULTS: The mean level of serum renalase was 75.8 ± 34.8 μg/mL. In the multivariable analysis, lower hemoglobin levels, higher serum creatinine levels, and diabetes mellitus were significantly associated with a higher renalase levels. Over the course of a mean follow-up period of 56 months, 25 deaths and 61 MACCEs occurred. Among 322 patients in whom these outcomes were assessed, 137 adverse renal outcomes occurred after a mean follow-up period of 27.8 months. Each 10- μg/mL increase in serum renalase was associated with significantly greater hazards of all-cause mortality and adverse renal outcomes (hazard ratio [HR] = 1.112, p = 0.049; HR = 1.052, p = 0.045). However, serum renalase level was not associated with the rate of MACCEs in patients with CKD. CONCLUSION: Our results indicated that circulating renalase might be a predictor of mortality and adverse renal outcomes in patients with CKD.

AB - BACKGROUND/AIMS: Patients with chronic kidney disease (CKD) have been found to show markedly increased rates of end-stage renal disease, major adverse cardiovascular and cerebrovascular events (MACCEs), and mortality. Therefore, new biomarkers are required for the early detection of such clinical outcomes in patients with CKD. We aimed to determine whether the level of circulating renalase was associated with CKD progression, MACCEs, and all-cause mortality, using data from a prospective randomized controlled study, Kremezin STudy Against Renal disease progression in Korea (K-STAR; NCT00860431). METHODS: A retrospective analysis of the K-STAR data was performed including 383 patients with CKD (mean age, 56.4 years; male/female, 252/131). We measured circulating renalase levels and examined the effects of these levels on clinical outcomes. RESULTS: The mean level of serum renalase was 75.8 ± 34.8 μg/mL. In the multivariable analysis, lower hemoglobin levels, higher serum creatinine levels, and diabetes mellitus were significantly associated with a higher renalase levels. Over the course of a mean follow-up period of 56 months, 25 deaths and 61 MACCEs occurred. Among 322 patients in whom these outcomes were assessed, 137 adverse renal outcomes occurred after a mean follow-up period of 27.8 months. Each 10- μg/mL increase in serum renalase was associated with significantly greater hazards of all-cause mortality and adverse renal outcomes (hazard ratio [HR] = 1.112, p = 0.049; HR = 1.052, p = 0.045). However, serum renalase level was not associated with the rate of MACCEs in patients with CKD. CONCLUSION: Our results indicated that circulating renalase might be a predictor of mortality and adverse renal outcomes in patients with CKD.

KW - Chronic kidney disease

KW - End-stage renal disease

KW - Mortality

KW - Renalase

UR - http://www.scopus.com/inward/record.url?scp=85046852413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046852413&partnerID=8YFLogxK

U2 - 10.3904/kjim.2017.058

DO - 10.3904/kjim.2017.058

M3 - Article

C2 - 29172403

AN - SCOPUS:85046852413

VL - 34

SP - 858

EP - 866

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 4

ER -